Journal
CRITICAL CARE
Volume 25, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s13054-021-03822-z
Keywords
Acute respiratory distress syndrome; Acute lung injury; Personalized medicine; COVID-19; Clinical trials
Categories
Funding
- NIH [5T32GM8440-24, UH3HL141722, K23-HL133489, R21-HL145506]
- [ANR-18-RHUS-0004]
Ask authors/readers for more resources
Identifying new effective treatments for ARDS, including COVID-19 ARDS, is challenging. The field is moving toward personalized therapy and recognizing the importance of the global context in finding effective treatments.
Identifying new effective treatments for the acute respiratory distress syndrome (ARDS), including COVID-19 ARDS, remains a challenge. The field of ARDS investigation is moving increasingly toward innovative approaches such as the personalization of therapy to biological and clinical sub-phenotypes. Additionally, there is growing recognition of the importance of the global context to identify effective ARDS treatments. This review highlights emerging opportunities and continued challenges for personalizing therapy for ARDS, from identifying treatable traits to innovative clinical trial design and recognition of patient-level factors as the field of critical care investigation moves forward into the twenty-first century.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available